Defendant
4 cases as defendant.
Hetero Drugs Limited ("Hetero") is an Indian pharmaceutical manufacturer headquartered at the Hetero Corporate Industrial Estate, Sanathnagar, Hyderabad, Telangana. It was founded in 1993 by Dr. Bandi Parthasaradhi Reddy, and is the founding entity of the privately held Hetero Group of Companies; the group's main operating company, Hetero Labs Limited, was incorporated in 1989 and is also unlisted. Hetero is not publicly traded — no ticker — and is described in its own materials as India's largest closely held pharmaceutical company. Hetero's 2025 factsheet cites a workforce of "30,000+," while Indian registry aggregators list far smaller headcounts (roughly 500–1,700) for the Hetero Drugs legal entity and FY2025 revenue above ₹10,000 crore for Hetero Labs; exact consolidated figures are not published, so these should be treated as approximate.
Operations. Hetero is a vertically integrated developer and manufacturer across five verticals: active pharmaceutical ingredients (450+ APIs, ~150 oncology APIs, 15 dedicated facilities); finished dosage forms/generics (550+ products, 23 facilities); biosimilars through Hetero Biopharma (17 programs, 9 commercialized); Custom Pharmaceutical Services (contract R&D and manufacturing of APIs, finished dosages, cytotoxic APIs and injectables); and "Global Access" supply to procurement bodies. It is among the world's largest suppliers of anti-retroviral APIs and formulations for HIV/AIDS (roughly 40% of global ARV demand, per company materials) and sells in 140+ countries. It launched generic injectable semaglutide in 2026.
Litigation posture. Hetero is an operating company defending, not asserting: it appears in the tracked data only as a defendant (3 of 3 cases, 0 as plaintiff), consistent with a generics manufacturer responding to Hatch-Waxman ANDA suits brought by brand owners. All tracked matters are in the District of New Jersey — Celgene's home district — not a plaintiff-friendly venue such as the Eastern District of Texas.
Notable cases. Celgene Corp. v. Hetero Labs Ltd. et al. (D.N.J., filed 2017-05-11) concerned Hetero's proposed generic version of Pomalyst (pomalidomide); a consent judgment entered August 19, 2021 enjoined Hetero's ANDA No. 210236 until expiration of the patents-in-suit. A related Celgene–Hetero lenalidomide (Revlimid) action, 2:20-cv-14389, ended in a September 27, 2021 consent judgment. These and parallel Celgene suits were later cited in purchaser and insurer antitrust complaints challenging Celgene's Revlimid/Pomalyst patent litigation and settlements. No views on the merits are expressed here.
Celgene sued Hetero entities in D.N.J. over generic lenalidomide. The docket was administratively terminated and consolidated under 2:20-cv-14389; a consent judgment/injunction was entered on September 27, 2021.
Hatch-Waxman ANDA litigation. The '427 was expressly named among the patents-in-suit, but Celgene withdrew its '427 infringement claims. Consolidated/coordinated for claim construction with 17-cv-03159. Case terminated 2021-08-19.
Celgene sued Hetero entities; aggregator data lists patent 7,119,106 as involved in this case, but the narrative flags this as unverified and notes the published opinions centered primarily on Pomalyst and later-expiring Revlimid patents rather than the expired '106 patent.
Celgene brought a §271(e)(2) ANDA action against Hetero in D.N.J. regarding the '428 patent. Hetero counterclaimed for declaratory judgment of invalidity/non-infringement of the '428 patent; the court issued a Markman ruling on 'treating multiple myeloma' in the '262, '3,939 and '428 patents, and the case was resolved by settlement.